First Trading Day of Q4, the New "CNBC Investing Club" With Jim Cramer, the Merck-Ridgeback Biotherapeutics COVID-19 Pill: An Interview With Ridgeback's Co-Founders. Plus, Zoom and Five9 Scrap Their $15B Deal.
b'Carl Quintanilla, Jim Cramer and David Faber kick off a new month and quarter by announcing details about Cramer launching the "CNBC Investing Club," which aims to help investors build long-term wealth. A big story out of Merck: The stock surging after the drug maker and its partner Ridgeback Biotherapeutics announced their experimental COVID-19 pill cut the risk of death and hospitalization by 50% in a late stage study. Both companies plan to file for emergency use authorization as soon as possible. Ridgeback Co-Founder Dr. Wayne Holman and Co-Founder and CEO Wendy Holman joined the program to discuss this big development in the war against the pandemic. Also in focus: Zoom Video and Five9 have terminated their nearly $15-billion deal by mutual consent, what to expect from the markets in the fourth quarter after a rough September, Exxon Mobil expects higher oil and gas prices to boost quarterly earnings by as much as $1.5-billion -- and Cathie Wood tweets about peak oil demand.'